Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Article Swipe

View

Bristol-Myers Squibb ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.25934/pr00011972

To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.

Related Topics

Concepts

Nivolumab Ipilimumab Medicine Oncology Internal medicine Clinical trial Metastatic melanoma Phases of clinical research Immunotherapy Renal cell carcinoma Adverse effect Melanoma CTLA-4 Blockade Expanded access

Metadata

Type: dataset
Language: en
Landing Page: https://doi.org/10.25934/pr00011972
OA Status: green
OpenAlex ID: https://openalex.org/W7106568033

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W7106568033

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.25934/pr00011972

Digital Object Identifier
Title: Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)

Work title
Type: dataset

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-11-24

Full publication date if available
Authors: Bristol-Myers Squibb

List of authors in order
Landing page: https://doi.org/10.25934/pr00011972

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: green

Open access status per OpenAlex
OA URL: https://doi.org/10.25934/pr00011972

Direct OA link when available
Concepts: Nivolumab, Ipilimumab, Medicine, Oncology, Internal medicine, Clinical trial, Metastatic melanoma, Phases of clinical research, Immunotherapy, Renal cell carcinoma, Adverse effect, Melanoma, CTLA-4, Blockade, Expanded access

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W7106568033
doi	https://doi.org/10.25934/pr00011972
ids.doi	https://doi.org/10.25934/pr00011972
ids.openalex	https://openalex.org/W7106568033
fwci
type	dataset
title	Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2780030458
concepts[0].level	4
concepts[0].score	0.9620024561882019
concepts[0].wikidata	https://www.wikidata.org/wiki/Q7041828
concepts[0].display_name	Nivolumab
concepts[1].id	https://openalex.org/C2781433595
concepts[1].level	4
concepts[1].score	0.9321002960205078
concepts[1].wikidata	https://www.wikidata.org/wiki/Q2459042
concepts[1].display_name	Ipilimumab
concepts[2].id	https://openalex.org/C71924100
concepts[2].level	0
concepts[2].score	0.87979656457901
concepts[2].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[2].display_name	Medicine
concepts[3].id	https://openalex.org/C143998085
concepts[3].level	1
concepts[3].score	0.6745093464851379
concepts[3].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[3].display_name	Oncology
concepts[4].id	https://openalex.org/C126322002
concepts[4].level	1
concepts[4].score	0.6453626751899719
concepts[4].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[4].display_name	Internal medicine
concepts[5].id	https://openalex.org/C535046627
concepts[5].level	2
concepts[5].score	0.6381524205207825
concepts[5].wikidata	https://www.wikidata.org/wiki/Q30612
concepts[5].display_name	Clinical trial
concepts[6].id	https://openalex.org/C2994587330
concepts[6].level	3
concepts[6].score	0.43756210803985596
concepts[6].wikidata	https://www.wikidata.org/wiki/Q180614
concepts[6].display_name	Metastatic melanoma
concepts[7].id	https://openalex.org/C31760486
concepts[7].level	3
concepts[7].score	0.41015002131462097
concepts[7].wikidata	https://www.wikidata.org/wiki/Q7180990
concepts[7].display_name	Phases of clinical research
concepts[8].id	https://openalex.org/C2777701055
concepts[8].level	3
concepts[8].score	0.38719215989112854
concepts[8].wikidata	https://www.wikidata.org/wiki/Q1427096
concepts[8].display_name	Immunotherapy
concepts[9].id	https://openalex.org/C2777472916
concepts[9].level	2
concepts[9].score	0.3565678596496582
concepts[9].wikidata	https://www.wikidata.org/wiki/Q1164529
concepts[9].display_name	Renal cell carcinoma
concepts[10].id	https://openalex.org/C197934379
concepts[10].level	2
concepts[10].score	0.3407071530818939
concepts[10].wikidata	https://www.wikidata.org/wiki/Q2047938
concepts[10].display_name	Adverse effect
concepts[11].id	https://openalex.org/C2777658100
concepts[11].level	2
concepts[11].score	0.28076422214508057
concepts[11].wikidata	https://www.wikidata.org/wiki/Q180614
concepts[11].display_name	Melanoma
concepts[12].id	https://openalex.org/C21705690
concepts[12].level	4
concepts[12].score	0.2693190574645996
concepts[12].wikidata	https://www.wikidata.org/wiki/Q2907609
concepts[12].display_name	CTLA-4
concepts[13].id	https://openalex.org/C2778468042
concepts[13].level	3
concepts[13].score	0.26568499207496643
concepts[13].wikidata	https://www.wikidata.org/wiki/Q273976
concepts[13].display_name	Blockade
concepts[14].id	https://openalex.org/C2775832928
concepts[14].level	2
concepts[14].score	0.25036299228668213
concepts[14].wikidata	https://www.wikidata.org/wiki/Q407954
concepts[14].display_name	Expanded access
keywords[0].id	https://openalex.org/keywords/nivolumab
keywords[0].score	0.9620024561882019
keywords[0].display_name	Nivolumab
keywords[1].id	https://openalex.org/keywords/ipilimumab
keywords[1].score	0.9321002960205078
keywords[1].display_name	Ipilimumab
keywords[2].id	https://openalex.org/keywords/clinical-trial
keywords[2].score	0.6381524205207825
keywords[2].display_name	Clinical trial
keywords[3].id	https://openalex.org/keywords/metastatic-melanoma
keywords[3].score	0.43756210803985596
keywords[3].display_name	Metastatic melanoma
keywords[4].id	https://openalex.org/keywords/phases-of-clinical-research
keywords[4].score	0.41015002131462097
keywords[4].display_name	Phases of clinical research
keywords[5].id	https://openalex.org/keywords/immunotherapy
keywords[5].score	0.38719215989112854
keywords[5].display_name	Immunotherapy
language	en
locations[0].id	doi:10.25934/pr00011972
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S7407053272
locations[0].source.type	repository
locations[0].source.is_oa	False
locations[0].source.issn_l
locations[0].source.is_core	False
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Vivli
locations[0].source.host_organization
locations[0].source.host_organization_name
locations[0].license
locations[0].pdf_url
locations[0].version
locations[0].raw_type	dataset
locations[0].license_id
locations[0].is_accepted	False
locations[0].is_published
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.25934/pr00011972
indexed_in	datacite
authorships[0].author.id	https://openalex.org/A4265177025
authorships[0].author.orcid
authorships[0].author.display_name	Bristol-Myers Squibb
authorships[0].countries	US
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210091812
authorships[0].affiliations[0].raw_affiliation_string	Bristol-Myers Squibb (United States)
authorships[0].institutions[0].id	https://openalex.org/I4210091812
authorships[0].institutions[0].ror	https://ror.org/00gtmwv55
authorships[0].institutions[0].type	company
authorships[0].institutions[0].lineage	https://openalex.org/I4210091812
authorships[0].institutions[0].country_code	US
authorships[0].institutions[0].display_name	Bristol-Myers Squibb (United States)
authorships[0].author_position	first
authorships[0].raw_author_name	Bristol Myers Squibb
authorships[0].is_corresponding	True
authorships[0].raw_affiliation_strings	Bristol-Myers Squibb (United States)
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.25934/pr00011972
open_access.oa_status	green
open_access.any_repository_has_fulltext	False
created_date	2025-11-25T00:00:00
display_name	Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
has_fulltext	False
is_retracted	False
updated_date	2025-11-27T01:12:40.094763
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.25934/pr00011972
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S7407053272
best_oa_location.source.type	repository
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l
best_oa_location.source.is_core	False
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Vivli
best_oa_location.source.host_organization
best_oa_location.source.host_organization_name
best_oa_location.license
best_oa_location.pdf_url
best_oa_location.version
best_oa_location.raw_type	dataset
best_oa_location.license_id
best_oa_location.is_accepted	False
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.25934/pr00011972
primary_location.id	doi:10.25934/pr00011972
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S7407053272
primary_location.source.type	repository
primary_location.source.is_oa	False
primary_location.source.issn_l
primary_location.source.is_core	False
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Vivli
primary_location.source.host_organization
primary_location.source.host_organization_name
primary_location.license
primary_location.pdf_url
primary_location.version
primary_location.raw_type	dataset
primary_location.license_id
primary_location.is_accepted	False
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.25934/pr00011972
publication_date	2025-11-24
publication_year	2025
referenced_works_count	0
abstract_inverted_index.To	0
abstract_inverted_index.in	6, 10
abstract_inverted_index.of	4
abstract_inverted_index.or	16
abstract_inverted_index.the	2
abstract_inverted_index.Cell	19
abstract_inverted_index.with	8, 12
abstract_inverted_index.Renal	18
abstract_inverted_index.safety	3
abstract_inverted_index.Cancer.	20
abstract_inverted_index.advanced	15
abstract_inverted_index.subjects	11
abstract_inverted_index.Nivolumab	5
abstract_inverted_index.untreated	14
abstract_inverted_index.Ipilimumab	9
abstract_inverted_index.metastatic	17
abstract_inverted_index.previously	13
abstract_inverted_index.combination	7
abstract_inverted_index.investigate	1
cited_by_percentile_year
countries_distinct_count	1
institutions_distinct_count	1
citation_normalized_percentile